Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "Where To Buy Sedatives"

Looking for quality documents?
corporate icon
ProConnex® Flow Paths
Customized, configurable and complete ProConnex® Flow Paths optimize fluid management and connectivity for specific TFF and TFDF Systems.
news icon
Prepacked Chromatography Columns; Evaluation for Use in Pilot and Large-Scale Bioprecessing
event icon
Downstream processing: Fully automated next-generation small-scale TFF solution with PAT control for GMP
corporate icon
Immobilized Protein A (IPA) Resins
Repligen Immobilized Protein A (IPA) resins are animal-free, and incorporates a recombinant Protein A ligand immobilized onto a highly cross-linked agarose bead.
corporate icon
PATsmart Downstream Consumables
Elevate your lab with top-of-the-line consumables tailored for the PATsmart SoloVPE PLUS and PATsmart FlowVPX systems, ensuring pristine measurements and accuracy in your scientific endeavors.
corporate icon
NGL-Impact® A Ligand
A next generation ligand co-developed by Repligen, NGL-Impact® A ligand is a paradigm-changing solution that can deliver higher performance, lower cost Protein A resin for capture chromatography.
external link icon
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin is being introduced at the BIO International Convention (BIO 2024), being held June 3-6 in San Diego. This latest innovation marks a significant milestone in Purolite’s long-term strategic partnership with Repligen, further solidifying Ecolab’s dedication to driving advancements in the bioprocessing industry. DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies, where cost of goods is critical for biologic drug developers. This new resin represents the latest addition to Purolite's toolbox, following two new resins launched in the last eighteen months to address purification challenges associated with
external link icon
UPDATE -- Repligen Acquires TangenX Technology Corporation
WALTHAM, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired TangenX Technology Corporation (“TangenX”) of Shrewsbury, MA, maker of the innovative single-use Sius™ line of tangential flow filtration (“TFF”) cassettes and hardware used in downstream biopharmaceutical manufacturing processes.  Sius TFF is used in the filtration of biological drugs, complementing Repligen’s OPUS® line of Pre-Packed Chromatography Columns used in downstream purification. Single-use Sius TFF cassettes are designed to deliver superior performance to traditional (reusable) TFF cassettes in a cost-competitive format that provides user-ready convenience and flexibility. The Sius portfolio also strengthens the Company’s existing capability in filtration, where its XCell™ ATF products (both stainless steel and single-use) are used for perfusion and cell culture intensification
external link icon
Repligen Hires Jon K. Snodgres as Chief Financial Officer
WALTHAM, Mass., July 15, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Jon K. Snodgres has been named its Chief Financial Officer. Mr. Snodgres joins Repligen from his CFO role at Maquet Cardiovascular, a medical device company. Over the course of five years with Maquet, Mr. Snodgres contributed to the company's growth from niche status to a diversified business generating over $1 billion in annual revenue. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific where he was Vice President of Finance for the Laboratory Products Group. At both Maquet and Thermo Fisher, Mr. Snodgres held key responsibility for numerous acquisitions and restructuring programs. He was also integral to the success of pricing and facility optimization programs that drove substantial earnings improvements. "I would like to welcome Jon to the Repligen management team," said Walter C. Herlihy, President and Chief Executive Officer of
external link icon
Repligen Appoints Jacob Johnson As Vice President Investor Relations
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, “Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth drivers for our industry and the company. Jacob has covered Repligen as a research analyst since 2019; his immediate familiarity with the company and our technologies will enable Jacob to seamlessly engage with the investor audience and pick up leadership of the IR function.” Mr. Garland added, “While